Why did BioNTech’s founders decide to leave?

They plan to create a new company focused on mRNA science and entrepreneurship. BioNTech framed the move as strategic, not abrupt, with a target exit by end-2026. The extended timeline should allow for a structured succession process while the founders pursue new platforms that could still connect to BioNTech through licenses and milestones.

What exactly moves to the new firm, and what stays at BioNTech?

Only selected rights and technologies will transfer. In return, BioNTech expects a minority stake, license rights, and potential milestones. The vaccine franchise and the core pipeline remain at BioNTech. The precise list of affected platforms and the royalty structure have not been disclosed yet, so investors should watch for more detail.

How did the market react to the news?

BNTX stock today fell 18.2% to $83.02, with intraday trading between $79.52 and $85.50 and volume far above average. The drop pushed shares close to the 52-week low of 81.20. The selloff reflects added leadership-transition risk and limited deal terms so far, rather than a confirmed loss of core commercial assets.

What should German investors monitor next?

Focus on the 13:30 CET earnings call for detail on the mRNA licensing deal, leadership continuity, and 2026 roadmaps. Track talent-retention measures, IP boundaries, and guidance on COVID and influenza demand. Technical levels around 81.20 are important. Note that analysts list 8 Buy and 2 Hold ratings, signaling cautious optimism despite uncertainty.

Global Market Insights

BNTX Stock Today, March 10: Founders Exit; Shares Drop 10% on Shock News

ByDanny Kontos March 10, 2026

BNTX stock today is under heavy pressure after BioNTech said co-founders Ugur Sahin and Özlem Türeci plan to leave by end-2026 to start a new mRNA-focused company. The U.S.-listed ADR BNTX fell 18.2% to $83.02, opening at $82.81, with volume far above average. BioNTech will transfer selected rights and technologies to the new venture for a minority stake, licenses, and milestones. For investors in Germany, the spotlight is on leadership transition, the mRNA licensing deal structure, and today’s earnings call scheduled for 13:30 CET.